UNC Institute for Global Health and Infectious Diseases researchers have begun phase 2 and phase 3 evaluations of promising treatments for COVID-19. The UNC School of Medicine joins more than 25 initial sites participating in the clinical trials through ACTIV-2, a public-private partnership sponsored by the NIH’s National Institute of Allergy and Infectious Diseases … Read more
A team of UNC researchers are partnering with colleagues at four institutions in Africa to study HIV-associated malignancies. With a five-year, $6 million grant from the NIH’s National Cancer Institute, the research consortium will look at screening and diagnosing innovations for three cancers common to people with HIV: Kaposi sarcoma, cervical cancer and lymphoma. Leading … Read more
In February 2020, as bits of data about the SARS-CoV-2 virus started to emerge, Cindy Gay, MD, MPH, and UNC infectious diseases colleagues began meeting to formulate a local response to the virus. They’ve met weekly ever since, resorting to Zoom calls once the university sent employees home in March. They’ve shared data, compared notes … Read more
The National Institutes of Health has awarded Myron Cohen, MD, director of UNC’s Institute for Global Health and Infectious Diseases, and FHI 360 $9.2 million to support research through the new COVID Prevention Network (CoVPN). The National Institute of Allergy and Infectious Diseases at the National Institutes of Health has formed the network to better … Read more
In the first COVID-19 case series of tocilizumab in the United States, UNC-Chapel Hill researchers report sobering results. They say the drug should be used judiciously until randomized clinical trials determine tocilizumab’s true efficacy. Meanwhile, medical students sidelined from clinical rotations by the virus conducted the research with lightning speed, all virtually. In the … Read more
Large-scale study funded by NIAID and ViiV Healthcare halted early after cabotegravir, dosed every two months, shows higher efficacy than daily oral pill. The decades-long search for a vaccine to prevent HIV reached a new milestone as results from HPTN 083, a global large-scale study, show that the long-acting drug cabotegravir (CAB LA) … Read more
A new study by the Multi-Drug-Resistant Organism Network of the Antibacterial Resistance Leadership Group (ARLG) has found that strains of carbapenem-resistant enterobacterales (CRE), a major threat to vulnerable patient populations, are more diverse than previously thought. The MDRO Network is led by UNC Infectious Diseases investigator David van Duin, MD, PhD. Analyzing patient … Read more
The Institute for Global Health and Infectious Diseases and UNC Project-Malawi were awarded a $4.5 million grant by the UK’s Fleming Fund to strengthen Malawi’s One Health Antimicrobial Resistance (AMR) program. The grant will support the national AMR coordination committee and technical working groups, supporting ownership and alignment and scaling up a One Health AMR mentoring scheme. In the human … Read more
Overcoming HIV latency – induction of HIV in CD4+ T cells that lay dormant throughout the body – is a major step toward creating a cure for HIV. For the first time, scientists at UNC-Chapel Hill, Emory University, and Qura Therapeutics – a partnership between UNC and ViiV Healthcare – have shown that a new … Read more
A team led by Jeff Stringer, MD, associate director of research for the Institute for Global Health & Infectious Diseases, has received $14 million from the Bill & Melinda Gates Foundation to conduct two studies aimed at improving pregnancy outcomes in the world’s poorest countries. The interdisciplinary group from departments within UNC’s School of Medicine … Read more
Researchers at UNC Project-Malawi published 124 articles in scientific journals in 2018, setting a record for UNC Institute for Global Health’s global sites. Twenty-six of the manuscripts featured Malawian first authors. “Our unit celebrates every publication manuscript coming from UNC Project-Malawi, especially those featuring a Malawian first author,” says Maga Chagomerana, PhD, the project’s director … Read more
